Therapies employing NK cells, which advantageously target tumor cells without MHC-dependent activation and are less likely than T cells to elicit severe side effects, are the topic of extensive research and dozens of clinical trials for both hematological and solid tumors, including lung cancer (15, 43). This evidence concerns the gene HLA-C and lung carcinoma.